Sinjard is a preparation of empagliflozin. Empagliflozin is an inhibitor of Sodium-glucose co-transporter 2 (SGLT2). SGLT2 is the predominant transporter responsible for reabsorption of glucose from the kidney back into the circulation. By inhibiting SGLT2, Empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion. Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and- to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.
|Generic Name||:||Empagliflozin INN|
|Available Pack Size||:||10 mg & 25 mg (Tablet)|
|Available Strength||:||Sinjard 10 Tablet (7 x 4’s), Sinjard 25 Tablet (7 x 2’s)|